Compare Sibanye Stillwater Ltd (SBSW) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Summit Therapeutics Inc — how do they compare? Sibanye Stillwater Ltd trades at $8.59 (market cap $5.66B), while Summit Therapeutics Inc trades at $14.57 (market cap $10.48B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 3.89% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SBSW | SMMT | |
|---|---|---|
Market Cap | $5.66B | $10.48B |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $29.32 |
52-Week Low | $7.27 | $13.05 |
Enterprise Value | $7.28B | $9.90B |
Dividend Yield | 3.89% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
